bpc-157 administration routes BPC 157 Dosage: A Doctor's Evidence-Based Guide BPC-157 Dosage Protocol: Injection Guide
Description
It supports healing of joint tissue, reduces inflammation, and can improve mobility
Commercial development was discontinued in 2007 after the Phase IIb trial failed to meet its primary endpoint
benefit: FDA only looked at risk, ignored benefits Off-label use: Doctors prescribe drugs off-label all the time Patient access: People are suffering and need options Regulatory capture: Big Pharma doesn't want cheap peptides competing The problem with these arguments: It's NOT off-label use Off-label only applies to FDA-approved drugs
Frontiers in Psychiatry
